Key Points AbbVie continues to diversify its portfolio into neuroscience and aesthetics to offset the loss of patent exclusivity for older drugs. Johnson & Johnson maintains a massive presence in medical technology alongside its traditional innovative medicine development. Which of these healthcare giants is the better fit for your income or growth portfolio today? 10 stocks we like better than AbbVie › Healthcare giants are navigating a landscape of patent expirations and regulatory shifts. Deciding between AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) requires weighing aggressive growth against diversified stability in a changing market.
Главную мысль мы показываем публично. Создайте бесплатный аккаунт, чтобы читать статью полностью, сохранять ее, обсуждать и связывать с рынками и OSINT-контекстом.